In a report released on September 27, Mara Goldstein from Mizuho Securities maintained IN8bio (INAB – Research Report) to a Buy, with a price target of $12.00.
Mara Goldstein’s Buy rating for IN8bio (INAB) is based on a number of key factors. First, Goldstein interprets the recent SITC titles release as largely positive for IN8bio, with the potential for additional valuable insights to emerge from the company’s R&D Day in October. This suggests a strong belief in the ongoing development and potential success of IN8bio’s research and development efforts.
Furthermore, Goldstein specifically highlights two posters that were part of the SITC release, namely #418 and #637. Poster #418 outlines the development of new manufacturing strategies for “Off-the-Shelf” iPSC-based Gamma-Delta T Cells, indicating innovation in the company’s production processes. Poster #637, on the other hand, details a Phase I study of gene modified autologous T cells in newly diagnosed glioblastoma patients, providing evidence for the company’s active engagement in promising new clinical trials. Both these factors contribute to Goldstein’s positive outlook and Buy rating for IN8bio.
INAB’s price has also changed moderately for the past six months – from $1.260 to $1.080, which is a -14.29% drop .
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
IN8bio (INAB) Company Description:
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Read More on INAB:
- IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
- IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
- IN8bio reports Q2 EPS (27c), consensus (27c)
- IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- IN8bio expands capabilities with opening of development facility in AL
